Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma

Diagnostic Cytopathology 2024 January 20 [Link] Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar Abstract Background: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which…

Read More

The knockdown of stathmin with si-RNA inhibits invasion of mesothelioma

Tissue and Cell 2024 January 5 [Link] Asude Aksoy, Asuman Varoglu, Ebru Etem Onalan, Ahmet Tektemur, Gokhan Artas, Mustafa Koc, Muharrem Cakmak, Siyami Aydin, Murat Kilic, Mustafa Ulas Abstract Background: To investigate the mechanism of action of stathmin1 (STMN1) in mesothelioma (MSM) and whether it has any role in its treatment. Methods: STMN1 expression was…

Read More

Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions

Archives of Pathology and Laboratory Medicine 2024 January 8 [Link] Yin P Hung, Lucian R Chirieac Abstract Context.—: Molecular testing has increasingly been utilized in the evaluation of mesothelioma. Diffuse mesothelioma comprises multiple distinct genetic subgroups. While most diffuse mesotheliomas lack oncogenic kinase mutations and instead harbor alterations involving tumor suppressors and chromatin regulators, a…

Read More

Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma

Modern Pathology 2024 January 5 [Link] Christopher A Febres-Aldana, Jason C Chang, Achim A Jungbluth, Prasad S Adusumilli, Francis M Bodd, Denise Frosina, Jerica A Geronimo, Enmily Hernandez, Helen Irawan, Michael D Offin, Natasha Rekhtman, William D Travis, Chad Vanderbilt, Marjorie G Zauderer, Yanming Zhang, Marc Ladanyi, Soo-Ryum Yang, Jennifer L Sauter Abstract 9p21 deletions…

Read More

PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma

Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…

Read More

Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…

Read More

Analysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma

Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…

Read More

LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

BMC Cancer 2023 December 7 [Link] Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya Abstract Background: Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs…

Read More

Formalin-Fixed Paraffin-Embedded Proteomics of Malignant Mesothelioma and New Candidate Biomarkers Thioredoxin and Superoxide Dismutase 2 for Immunohistochemistry

Laboratory Investigation 2023 November [Link] Takuya Hiratsuka, Akihiko Yoshizawa, Tatsuya Endo, Takushi Yamamoto, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract The pathogenesis of malignant mesothelioma (MM) has been extensively investigated, focusing on stress derived from reactive oxygen species. We aimed to identify diagnostic biomarkers of MM by analyzing proteins in formalin-fixed paraffin-embedded specimens using liquid chromatography-mass spectrometry.…

Read More

Salvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma

Interdisciplinary Cardiovascular and Thoracic Surgery 2023 November 15 [Link] Masaru Takenaka, Koji Kuroda, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Fumihiro Tanaka Abstract Salvage surgery following immunotherapy is a promising treatment option for advanced malignant tumour. However, only a few cases of salvage surgery for malignant pleural mesothelioma (MPM) have been reported.…

Read More